Ardelyx, which is developing therapies to control the progression of late-stage kidney disease, raised $60 million by offering 4.3 million shares (vs. 3.6 million originally planned) at $14, the midpoint of its $13 to $15 range. Ardelyx will list on the NASDAQ under the symbol ARDX. Citi and Leerink Partners acted as joint bookrunners on the deal.
